About Pasithea Therapeutics Corp.
http://pasitheaclinics.comPasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine.
CEO
Tiago Reis Marques
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
KEPOS CAPITAL LP
Shares:334.6K
Value:$3.68K
ARMISTICE CAPITAL, LLC
Shares:50K
Value:$550
MAREX GROUP PLC
Shares:25K
Value:$275
Summary
Showing Top 3 of 7
About Pasithea Therapeutics Corp.
http://pasitheaclinics.comPasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $2.93M ▼ | $-3.04M ▲ | 0% | $-0.41 ▲ | $-2.86M ▲ |
| Q2-2025 | $0 | $3.81M ▲ | $-3.72M ▼ | 0% | $-0.66 ▲ | $-3.65M ▼ |
| Q1-2025 | $0 | $3.68M ▲ | $-3.56M ▼ | 0% | $-3.25 ▼ | $-3.52M ▼ |
| Q4-2024 | $0 | $3.1M ▲ | $-3.18M ▼ | 0% | $-2.9 ▼ | $-3.02M ▼ |
| Q3-2024 | $0 | $3M | $-3M | 0% | $-2.87 | $-2.84M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.12M ▼ | $13.63M ▼ | $1.42M ▼ | $12.21M ▼ |
| Q2-2025 | $7.22M ▲ | $17.01M ▲ | $1.83M ▲ | $15.18M ▲ |
| Q1-2025 | $5.34M ▼ | $14.66M ▼ | $1.68M ▲ | $12.98M ▼ |
| Q4-2024 | $6.92M ▼ | $16.06M ▼ | $1.28M ▲ | $14.78M ▼ |
| Q3-2024 | $9.36M | $18.64M | $823.98K | $17.81M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.04M ▲ | $-2.89M ▲ | $0 | $-116.14K ▼ | $-2.99M ▼ | $-2.89M ▲ |
| Q2-2025 | $-3.72M ▼ | $-3.87M ▼ | $0 | $5.74M ▲ | $1.88M ▲ | $-3.87M ▼ |
| Q1-2025 | $-3.56M ▼ | $-3.06M ▼ | $0 | $1.47M ▲ | $-1.58M ▲ | $-3.06M ▼ |
| Q4-2024 | $-3.18M ▼ | $-2.44M ▲ | $0 | $-23.55K ▼ | $-2.44M ▼ | $-2.44M ▲ |
| Q3-2024 | $-3M | $-3.12M | $0 | $4.54M | $1.39M | $-3.12M |
CEO
Tiago Reis Marques
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
KEPOS CAPITAL LP
Shares:334.6K
Value:$3.68K
ARMISTICE CAPITAL, LLC
Shares:50K
Value:$550
MAREX GROUP PLC
Shares:25K
Value:$275
Summary
Showing Top 3 of 7